FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users
August 2015
Stacie Ropka, PhD and Chad Landmon
GxP Lifeline
Axinn Counsel Stacie Ropka and Partner Chad Landmon authored, "FDA Regulation of CT/Ps – Impact of New Guidances on Manufacturers and Users," which was published in MasterControl's GxP Lifeline newsletter.
Click here to read the article.